News & Press

MRF 25th Anniversary: Managing Immunotherapy-Related Treatment Side Effects

March 24, 2021

For our 25th anniversary, we share a guest blog from Douglas B. Johnson, MD, MSCI, from Vanderbilt Medical Center and recipient of a research grant provided by the MRF/MRF Breakthrough Consortium:  “Patient with metastatic melanoma” – these words carri …

Leading Skin Cancer Organizations Urge the FDA to Ban Tanning Beds for Minors

March 12, 2021

WASHINGTON, DC – The Melanoma Research Foundation (MRF) recently signed- on to a letter from the National Council of Skin Cancer Prevention (NCSCP) urging the U.S. Food and Drug Administration (FDA) to finalize the proposed rules entitled General and P …

FDA Grants Alkermes Orphan Drug Designation for the Treatment of Mucosal Melanoma

March 11, 2021

WASHINGTON, DC – The U.S. Food and Drug Administration (FDA) has recently granted orphan drug designation for the treatment of mucosal melanoma to Alkermes’ investigational engineered interleukin-2 (IL-2) variant immunotherapy, nemvaleukin alfa (“nemva …

#EyeGetDilated: Alton Pace in Memory of Daryl Pace

February 26, 2021

Guest blog from Alton Pace in memory of his half-sister Daryl who passed away from ocular melanoma: “Take care of your eyeballs!” This is what my sister Daryl would often say to me years before her ocular melanoma (OM) diagnosis. Being a teenager at th …

A Focus on Rare Melanoma Subtypes

February 26, 2021

Guest blog post from Mark Weinzierl, MRF board member and ocular melanoma survivor: My name is Mark Weinzierl and I am currently a board member of the Melanoma Research Foundation (MRF), the largest independent organization devoted to melanoma. My inte …